Drugs / CT0590
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT05066022 | Oct 2021 → Aug 2022 | refractory plasma cell neoplasm | The First Affiliated Hospital of Soochow University | Unknown | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2024-11-06 | CARsgen Therapeutics Co., Ltd. | CARsgen ® to Present Zevor-cel, CT071 and CT0590 at ASH 2024 Annual Congress carsgen.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CT0590 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05066022 ↗ |
| Modality | Cell therapy | “CT0590 Chimeric Antigen Receptor T Cell （CAR T）” NCT05066022 ↗ |